Recent Research Analysts’ Ratings Updates for Vaxcyte (PCVX)

Vaxcyte (NASDAQ: PCVX) has recently received a number of price target changes and ratings updates:

• 10/5/2026 – Vaxcyte had its price target raised by Guggenheim from $116.00 to $125.00. They now have a “buy” rating on the stock.
• 10/5/2026 – Vaxcyte had its “buy” rating reaffirmed by BTIG Research. They now have a $89.00 price target on the stock.
• 10/5/2026 – Vaxcyte had its price target raised by Needham & Company LLC from $110.00 to $122.00. They now have a “buy” rating on the stock.
• 10/2/2026 – Vaxcyte had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/28/2026 – Vaxcyte had its price target lowered by Bank of America Corporation from $133.00 to $130.00. They now have a “buy” rating on the stock.
• 9/25/2026 – Vaxcyte had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $110.00 price target on the stock.
• 8/12/2026 – Vaxcyte was upgraded by Zacks Research from “strong sell” to “hold”.

Insider Buying and Selling

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $53.89, for a total value of $538,900.00. Following the completion of the transaction, the chief financial officer directly owned 105,176 shares in the company, valued at approximately $5,667,934.64. This represents a 8.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet Dhaliwal sold 17,000 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total transaction of $935,000.00. Following the completion of the sale, the insider directly owned 76,756 shares in the company, valued at approximately $4,221,580. This represents a 18.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 92,890 shares of company stock valued at $6,320,569 over the last three months. Insiders own 3.30% of the company’s stock.

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.